ARFGAP2

Across TCGA pan-cancer cohorts, ARFGAP2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARFGAP2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARFGAP2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARFGAP2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, LUAD, and COAD are the cancer types where ARFGAP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARFGAP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.215	<.001	11	view →
LUAD	Female	All	+0.269	<.001	9	view →
COAD	Male	All	+0.252	<.001	9	view →
PDAC	Male	All	−0.474	<.001	8	view →
LSCC	All	All	+0.152	<.001	5	view →
OV	All	All	+0.282	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARFGAP2–CCRCC

Open the CCRCC breakdown →